Literature DB >> 36273114

Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?

Koji Kato1.   

Abstract

Entities:  

Keywords:  B-cell lymphoma; EZH2; Epigenetics; Lymphocyte; T-cell lymphoma

Year:  2022        PMID： 36273114     DOI： 10.1007/s12185-022-03472-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.319


× No keyword cloud information.
  10 in total

1.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

2.  Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.

Authors:  Shan He; Jina Wang; Koji Kato; Fang Xie; Sooryanarayana Varambally; Shin Mineishi; Rork Kuick; Kazuhiro Mochizuki; Yongnian Liu; Evelyn Nieves; Ram-Shankar Mani; Arul M Chinnaiyan; Victor E Marquez; Yi Zhang
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

3.  Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.

Authors:  Makoto Yamagishi; Makoto Hori; Dai Fujikawa; Takeo Ohsugi; Daisuke Honma; Nobuaki Adachi; Harutaka Katano; Tsunekazu Hishima; Seiichiro Kobayashi; Kazumi Nakano; Makoto Nakashima; Masako Iwanaga; Atae Utsunomiya; Yuetsu Tanaka; Seiji Okada; Kunihiro Tsukasaki; Kensei Tobinai; Kazushi Araki; Toshiki Watanabe; Kaoru Uchimaru
Journal:  Cell Rep       Date:  2019-11-19       Impact factor: 9.423

4.  Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

Authors:  Franck Morschhauser; Hervé Tilly; Aristeidis Chaidos; Pamela McKay; Tycel Phillips; Sarit Assouline; Connie Lee Batlevi; Phillip Campbell; Vincent Ribrag; Gandhi Laurent Damaj; Michael Dickinson; Wojciech Jurczak; Maciej Kazmierczak; Stephen Opat; John Radford; Anna Schmitt; Jay Yang; Jennifer Whalen; Shefali Agarwal; Deyaa Adib; Gilles Salles
Journal:  Lancet Oncol       Date:  2020-10-06       Impact factor: 41.316

5.  BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.

Authors:  Michael C Zaiken; Ryan Flynn; Katelyn G Paz; Stephanie Y Rhee; Sujeong Jin; Fathima A Mohamed; Asim Saha; Govindarajan Thangavelu; Paul M C Park; Matthew L Hemming; Peter T Sage; Arlene H Sharpe; Michel DuPage; Jeffrey A Bluestone; Angela Panoskaltsis-Mortari; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Leo Luznik; Ivan Maillard; Geoffrey R Hill; Kelli P A MacDonald; David H Munn; Jonathan S Serody; William J Murphy; Leslie S Kean; Yi Zhang; James E Bradner; Jun Qi; Bruce R Blazar
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

6.  Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Authors:  Daisuke Ennishi; Katsuyoshi Takata; Wendy Béguelin; Gerben Duns; Anja Mottok; Pedro Farinha; Ali Bashashati; Saeed Saberi; Merrill Boyle; Barbara Meissner; Susana Ben-Neriah; Bruce W Woolcock; Adèle Telenius; Daniel Lai; Matt Teater; Robert Kridel; Kerry J Savage; Laurie H Sehn; Ryan D Morin; Marco A Marra; Sohrab P Shah; Joseph M Connors; Randy D Gascoyne; David W Scott; Ari M Melnick; Christian Steidl
Journal:  Cancer Discov       Date:  2019-01-31       Impact factor: 39.397

7.  Polycomb-dependent epigenetic landscape in adult T-cell leukemia.

Authors:  Dai Fujikawa; Shota Nakagawa; Makoto Hori; Naoya Kurokawa; Ai Soejima; Kazumi Nakano; Tadanori Yamochi; Makoto Nakashima; Seiichiro Kobayashi; Yuetsu Tanaka; Masako Iwanaga; Atae Utsunomiya; Kaoru Uchimaru; Makoto Yamagishi; Toshiki Watanabe
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

8.  Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.

Authors:  Kevin R Parker; Elena Sotillo; Evan W Weber; Rachel C Lynn; Hima Anbunathan; John Lattin; Zinaida Good; Julia A Belk; Bence Daniel; Dorota Klysz; Meena Malipatlolla; Peng Xu; Malek Bashti; Sabine Heitzeneder; Louai Labanieh; Panayiotis Vandris; Robbie G Majzner; Yanyan Qi; Katalin Sandor; Ling-Chun Chen; Snehit Prabhu; Andrew J Gentles; Thomas J Wandless; Ansuman T Satpathy; Howard Y Chang; Crystal L Mackall
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728

9.  Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.

Authors:  Katsuyoshi Takata; Lauren C Chong; Daisuke Ennishi; Tomohiro Aoki; Michael Yu Li; Avinash Thakur; Shannon Healy; Elena Viganò; Tao Dao; Daniel Kwon; Gerben Duns; Julie S Nielsen; Susana Ben-Neriah; Ethan Tse; Stacy S Hung; Merrill Boyle; Sung Soo Mun; Christopher M Bourne; Bruce Woolcock; Adèle Telenius; Makoto Kishida; Shinya Rai; Allen W Zhang; Ali Bashashati; Saeed Saberi; Gianluca D'Antonio; Brad H Nelson; Sohrab P Shah; Pamela A Hoodless; Ari M Melnick; Randy D Gascoyne; Joseph M Connors; David A Scheinberg; Wendy Béguelin; David W Scott; Christian Steidl
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

10.  Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity.

Authors:  Shan He; Yongnian Liu; Lijun Meng; Hongxing Sun; Ying Wang; Yun Ji; Janaki Purushe; Pan Chen; Changhong Li; Jozef Madzo; Jean-Pierre Issa; Jonathan Soboloff; Ran Reshef; Bethany Moore; Luca Gattinoni; Yi Zhang
Journal:  Nat Commun       Date:  2017-12-14       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.